ASTRAZENECA PLC Reports Fourth Quarter FY2022 Earnings on February 9, 2023.

Earnings Overview

On February 9, 2023, ASTRAZENECA PLC ($LSE:AZN) reported their fourth quarter earnings for FY2022, ending December 31, 2022. Revenue for the quarter was USD 901.0 million, a 359.7% year-on-year increase; however, net income decreased 6.7% year-on-year, totaling USD 11207.0 million.

Price History

On Thursday, February 9th, 2023, ASTRAZENECA PLC reported their fourth quarter financial results for the FY2022. The stock opened at £110.4, before closing at £111.9, which represented a 4.1% increase from the previous closing price of £107.5. This increase came despite overall volatility in the market, suggesting that investors remain confident that ASTRAZENECA PLC’s performance over the past year has been strong. This growth was largely driven by the success of their new drugs, which were well received in the market.

Furthermore, ASTRAZENECA PLC’s research and development budget increased significantly, suggesting a commitment to further innovation and growth in the future. Overall, ASTRAZENECA PLC’s fourth quarter financial results indicate a healthy and profitable future for the company. Investors will be eagerly awaiting the company’s next earnings report to see if this trend will continue. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…

Key Ratios Snapshot

Some of the financial key ratios for Astrazeneca Plc are shown below. More…

Analysis

At GoodWhale, we’ve taken a deep-dive into the fundamentals of ASTRAZENECA PLC and can confidently say that it’s a medium risk investment in terms of financial and business aspects. We’ve identified two potential risks that could affect the company’s performance, which can be seen on their income sheet and balance sheet. However, to access more information on this, you would need to become a registered user with GoodWhale. Once you’re registered, you’ll be able to see a full breakdown of the risk factors associated with ASTRAZENECA PLC, along with other detailed analysis. More…

Peers

AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.

– Sanofi SA ($OTCPK:SNYNF)

As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.

Summary

Investors in AstraZeneca PLC (AZN) were pleased with the company’s fourth quarter financial results for FY2022, as total revenue increased by 359.7% year-on-year. However, despite the strong revenue growth, net income decreased by 6.7% due to operational costs. Nevertheless, AZN’s share price still moved upwards on the news, suggesting that investors remain confident in the company’s ability to extend its financial success into the future. Looking ahead, investors will be watching for AZN’s progress in the development of novel treatments and therapies, as well as its efforts to expand into new markets.